In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique

This article was originally published in The Pink Sheet Daily

Executive Summary

"Restroom stall cling" for the urinary incontinence drug used at medical meeting gets notice of violation letter from DDMAC.
Advertisement

Related Content

Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says
Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says
Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion
FDA Objects To Proximity Of Ferrlecit Reminder And Unbranded Ads

Topics

Advertisement
UsernamePublicRestriction

Register

PS071604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel